%0 Journal Article
%9 ACL : Articles dans des revues avec comité de lecture répertoriées par l'AERES
%A Mastrangelo, E.
%A Pezzullo, M.
%A De Burghgraeve, T.
%A Kaptein, S.
%A Pastorino, B.
%A Dallmeier, K.
%A de Lamballerie, Xavier
%A Neyts, J.
%A Hanson, A. M.
%A Frick, D. N.
%A Bolognesi, M.
%A Milani, M.
%T Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity : new prospects for an old drug
%D 2012
%L PAR00009129
%G ENG
%J Journal of Antimicrobial Chemotherapy
%@ 0305-7453
%K antiviral drug discovery ; flavivirus helicase inhibition ; new use of existing drug ; in silico docking ; structure-based drug design
%M ISI:000306366000014
%N 8
%P 1884-1894
%R 10.1093/jac/dks147
%U https://www.documentation.ird.fr/hor/PAR00009129
%V 67
%W Horizon (IRD)
%X Infection with yellow fever virus (YFV), the prototypic mosquito-borne flavivirus, causes severe febrile disease with haemorrhage, multi-organ failure and a high mortality. Moreover, in recent years the Flavivirus genus has gained further attention due to re-emergence and increasing incidence of West Nile, dengue and Japanese encephalitis viruses. Potent and safe antivirals are urgently needed. Starting from the crystal structure of the NS3 helicase from Kunjin virus (an Australian variant of West Nile virus), we identified a novel, unexploited protein site that might be involved in the helicase catalytic cycle and could thus in principle be targeted for enzyme inhibition. In silico docking of a library of small molecules allowed us to identify a few selected compounds with high predicted affinity for the new site. Their activity against helicases from several flaviviruses was confirmed in in vitro helicase/enzymatic assays. The effect on the in vitro replication of flaviviruses was then evaluated. Ivermectin, a broadly used anti-helminthic drug, proved to be a highly potent inhibitor of YFV replication (EC50 values in the sub-nanomolar range). Moreover, ivermectin inhibited, although less efficiently, the replication of several other flaviviruses, i.e. dengue fever, Japanese encephalitis and tick-borne encephalitis viruses. Ivermectin exerts its effect at a timepoint that coincides with the onset of intracellular viral RNA synthesis, as expected for a molecule that specifically targets the viral helicase. The well-tolerated drug ivermectin may hold great potential for treatment of YFV infections. Furthermore, structure-based optimization may result in analogues exerting potent activity against flaviviruses other than YFV.
%$ 052 ; 050